Session Abstract – PMWC 2026 Silicon Valley
The PMWC 2026 Genomic Profiling Showcase will provide a 15-30 min speaking opportunity for selected companies working with the latest technologies in nucleic acid sequencing such as NGS, providing instrumentation for genomic sequencing, and offering direct to consumer services. These companies will share their innovative products and services to an audience of leading investors, potential clients and partners. The Genomic Profiling Showcase will exhibit the latest innovations in methods and instruments used for DNA/ RNA sequencing to ascertain the genomic and transcriptional profile of a person in order to understand why some people get certain diseases while others do not, or why people react in different ways to the same drug. This information is also being used to develop new ways to diagnose, treat, and prevent diseases, such as cancer.
Confirmed Presenting Companies:
Speaker Profile
M.D., Chief Executive Officer, BioAro
Biography
Dr. Anmol S. Kapoor is a cardiologist, entrepreneur, and founder of BioAro, a next-generation precision health company integrating genomics, multi-omics, and advanced AI to transform clinical care. Under his leadership, BioAro has built a global ecosystem spanning whole-genome and cancer sequencing, pharmacogenomics, microbiome testing, telomere biology, and longevity sciences.Driven to bridge the gaps of traditional medicine, Dr. Kapoor is advancing a prediction-, prevention-, and personalization-focused model that empowers clinicians across cardiology, oncology, dermatology, gastroenterology, gynecology, and longevity medicine.He also founded PanOmiQ, an AI-powered therapy-selection and multi-omics platform, and pioneered BioEMRBioELR, next-generation electronic record systems integrating AI into everyday practice. Through Kapoor Wealth Partners, he supports breakthrough ventures in medtech, biotech, digital health, and longevity.Internationally recognized in digital health and multi-omics innovation, Dr. Kapoor is shaping the global adoption of data-driven, patient-centered healthcare.
Talk
MultiOmics and AI: Pioneering the future of Longevity
MultiOmics and AI are redefining longevity science by uncovering hidden drivers of aging and enabling ultra-personalized prevention. This talk explores how integrated genomics, proteomics, microbiome insights, and AI-driven prediction models are transforming early detection, therapeutic targeting, and real-time health optimization shaping a new era of precision, preventive, and proactive longevity medicine.
Genomic Profiling Showcase:
BioAro Inc.
BioAro advances longevity through AI, LLM-powered BioIntelligence, and Axion hardware, integrating genomics, multi-omics lab testing, and real-time analysis. Its PanOmiQ platform unifies DNA, microbiome, and metabolic insights to deliver predictive, personalized, and proactive precision health.
Speaker Profile
Ph.D., Chief Executive Officer, Clareo Biosciences
Biography
Dr. Smith obtained her PhD at Harvard University, and trained further at Insitut Pasteur, Paris and University of California, San Diego. Dr. Smith focuses on the development of disruptive technologies at the intersection of genomics, immunology, and virology. The primary goal of all of her work is to overcome prior technical limitations with innovative approaches that provide unparalleled resolution of the human immune system, enabling the development of effective and efficient precision therapeutic approaches.
Talk
Decoding immune diversity to deliver precision therapeutics
The Clairity platform delivers comprehensive personalized immune profiling enabling AIML-based modeling for targeted drug design, therapeutic response prediction, and autoimmunity risk assessment. We'll showcase key competitive differentiators, highlight multiple proven successes across diverse applications, and present our detailed roadmap toward companion diagnostics development, bridging immune diversity insights with precision medicine.
Genomic Profiling Showcase:
Clareo Biosciences, Inc.
Clareo Biosciences delivers the world's first comprehensive immune receptor profiling through the Clairty platform. Our complete immunogenomic intelligence enables companion diagnostics, predictive biomarkers, and precision drug design—accelerating therapeutic development, improving patient outcomes, and reducing adverse events across immunotherapy, vaccines, and autoimmunity.
